about
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cellsThree years of experience: the Italian registry and safety data update.Clinical baseline factors predict response to natalizumab: their usefulness in patient selectionNeuroprotective features of mesenchymal stem cells.Mesenchymal stem cells as treatment for MS - progress to date.Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection.Regulatory Functions of Natural Killer Cells in Multiple Sclerosis.In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma.Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.Teriflunomide treatment reduces B cells in patients with MS.Long-term disability progression in primary progressive multiple sclerosis: a 15-year study.Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis.Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MSUrinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk StratificationA case of thyroiditis during natalizumab therapy for multiple sclerosisAssociation of melanoma and natalizumab therapy in the Italian MS population: a second case reportCan we kill an extra bird with the same stone?Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuationApproved drugs for multiple sclerosis: the challenge of choiceImpact of treatment on cellular immunophenotype in MS: A cross-sectional studyCardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimodDeterminants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life studyFactors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online surveySerum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case reportNo evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyClinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter studyOutcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort studyExtending the Interval of Natalizumab Dosing: Is Efficacy Preserved?Enhancing natural killer cells is beneficial in multiple sclerosis - YesCD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis
P50
Q24293709-09F6AF4C-CF93-4CF7-8E6A-6362B73FDD4EQ33636476-BDF443DF-CA73-4C79-B961-29E80EE3E4BAQ33712682-D94E0177-695F-4D97-BEFA-924F2967497FQ37852225-4A74C448-0A35-475C-85A6-75B074838312Q38057682-BDDF624B-186A-4A61-A879-D55F1B112D1AQ38571209-0426C60B-2D4C-4549-833D-51EC1D82AF10Q39032832-E3931DEF-83EB-4CE1-BA58-FFACA79CA77FQ39128925-6F0407B5-8A3D-4A2E-BFC5-43139764C474Q40222288-17F575B2-01AF-491A-9712-43F25B9B641BQ40498932-F8CE0B4A-C324-4A1F-86ED-3A0438770BD7Q47237142-19801119-8BA4-4AB7-9225-F74E4F88E599Q48009677-4531894E-6271-4B68-A778-0B83847B9A72Q50597243-7F52E2ED-31D7-44A7-9282-4CD0916CC1CAQ52651142-E2CBBC37-6A19-4B92-8556-A9549166F03CQ55059713-3B4C2F50-9C62-4542-915B-B04AF9647460Q61657725-F0C459C4-34DC-48E7-9A22-3211914CF49EQ61657742-8458352D-E52C-4B48-BC8C-F4E74E72C469Q61657743-C117E833-6F1C-466E-8EF3-C52EB9EF1026Q61657746-28BA5DC5-CAA8-4720-A137-D7709C801D72Q61657748-241D190C-FB1B-4C8C-A79E-E3A6531C90AFQ88511589-FD4D49CE-1BEB-4D58-8C0B-4EFD8EE41CEBQ89296986-A0997D38-363F-4BF7-B6A1-58C6126D0948Q90089343-3D329A70-8E81-4888-AC00-7CD5C2D25D43Q90105734-FCD98E2D-33B2-4B05-BEF9-FAA814329C85Q90463758-C793D762-EBE5-40D3-87FD-67B6C97E4A15Q91073072-1F277662-6F3A-448F-A95C-7FBEAF016CD4Q91485546-3E6F83C2-9D75-49E6-8C26-9CD7A9B0DB0CQ91794541-F2E82C4E-A7B4-47EE-9F3F-7B5BDECEC7E8Q92566889-F860FD90-2D8F-4B9E-B15C-341668CC8450Q92828116-8C1F8E6F-79A7-45C3-AE5E-7EB845B198ABQ92885645-0F4873D9-D683-4BFC-9FDB-99F7466A1A0AQ93025690-001CD3D2-F303-48CF-BE6A-511574801E3FQ94945251-C18722A5-D845-44EC-873A-C0A228D7FB53
P50
description
researcher ORCID ID = 0000-0001-5599-9788
@en
wetenschapper
@nl
name
Alice Laroni
@ast
Alice Laroni
@en
Alice Laroni
@es
Alice Laroni
@nl
type
label
Alice Laroni
@ast
Alice Laroni
@en
Alice Laroni
@es
Alice Laroni
@nl
prefLabel
Alice Laroni
@ast
Alice Laroni
@en
Alice Laroni
@es
Alice Laroni
@nl
P106
P21
P31
P496
0000-0001-5599-9788